Samama, C M <br/><br/>
[Bounderies of the authorization to market and the therapeutic impass].  [electronic resource] 

 -  Annales francaises d'anesthesie et de reanimation  Jun 2001 
 - 507-8 p.  digital 
<br/><br/> Publication Type: Editorial 
<br/><br/><label>ISSN: </label>0750-7658 
<br/><br/><label>Standard No.: </label>10.1016/s0750-7658(01)00438-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anticoagulants--adverse effects<br/>Chondroitin Sulfates--adverse effects<br/>Dermatan Sulfate--adverse effects<br/>Drug Approval--legislation & jurisprudence<br/>Drug Combinations<br/>France<br/>Heparin--adverse effects<br/>Heparitin Sulfate--adverse effects<br/>Hirudin Therapy<br/>Hirudins--adverse effects<br/>Humans<br/>Recombinant Proteins--adverse effects